Molecules are the code of life. AI is the compiler.

The clock does not only tick forward

Wire science to blockspace and hit the gas

Less than 2 hours left in the $AUBRAI Ignition Sale!

> 13.8X oversubscribed
> 1660+ participants!

We're working through some front-end bugs - rest assured, if BioXP + $BIO have left your wallet you'll be included in the sale.

IGNITION COMPLETED

> 14.6X oversubscribed
> 1,861 participants
> 3.4M $BIO committed

Sale is now being finalized and allocations determined.

$AUBRAI is expected to go live for trading tomorrow, August 27.

Get the latest updates on Bio's app:
https://app.bio.xyz/agents/aubrai

Bio is now live on
@MaestroBots
🤖

Trade BioAgents, BioDAOs and IP-Tokens directly in Telegram.
That includes $AUBRAI, the first BioAgent, soon to be tradable straight from TG.

Create a wallet, send ETH, and start trading on Base today ↓

Following AUBRAI’s 14x oversubscribed Ignition Sale, the TGE is set to go live later today on
@base


> Claiming & swapping: Users can claim/swap AUBRAI in the Bio App

> Anti-Jeeting: users who purchased AUBRAI in the Ignition Sale who sell >50% in the first 2 weeks get locked in BioXP jail for 3 weeks

> Liquidity pair: BIO/AUBRAI pool funded in part by BIO raised in the sale, generating protocol-owned liquidity

Aubrai will then be going live in the stages with Aubrai Chat getting rolled out to researchers and holders, and the Aubrai community getting first access to new IP-Tokens minted from Aubrai's knowledge.

More soon, stay locked: https://app.bio.xyz/agents/aubrai

The Internet of Science should flow freely.

Uniting researchers and citizen scientists as never before.

Just as Substack help writers break free from traditional media, BioAgents help scientists build and monetize their research outside traditional pharma.

AUBRAI staking is live!

Plug your $AUBRAI into the knowledge economy:

> Stake AUBRAI on the Bio App
> Earn BioXP
> Use BioXP in upcoming IP-Token & BioAgent sales

Capital is compute.

gbio 🌱

A biotech renaissance is emerging in the East.

Fearless founders, regulatory agility, massive capital inflows.

This month & next, we're touring Asia with DeSci summits, a bio/acc rave & countless IRL meetings.

Here are some places we’ll be. RSVP links below. DM to meet.

Captain Science

The next leap has already started.

$DICK is live & liquid on Bio!

@D1ckGPT
is your AI-personalized men's health agent built to track & reverse your D-Age. Trained on clinician-curated research and live studies by
@D1ckDAO
researchers, the agent is engineered to reverse men's biological aging through science-backed health optimization.

CA: 0xE183b1A4DD59Ca732211678EcA1836EE35bCE582

Claim and swap DICK in the Bio App: https://app.bio.xyz/agents/d1ckgpt

→ Selling >50% of your Ignition allocation within the first 2 weeks results in your BioXP earning power being paused for 3 weeks.

→ A BIO/DICK liquidity pool is now live supporting trading in the token and generating a continuous stream of research funding for the D1ckGPT team to execute on their roadmap and finance experiments that feed the agent data & value.

→ Staking for $DICK will go live soon, allowing you to earn more BioXP for the next Ignition Sales.

See the project roadmap below and use the
@D1ckGPT
agent for men's health advice & research.

Last week in the Biosphere:

• VitaSTEM, the 1st
@Aubrai_
IP Token, shows how humans + AI Agents can co-drive R&D

• Men’s Health BioAgent
@D1ckGPT
launches w/ Thailand-based doctors

•
@Aubrai_
hits funding milestone

• BioXP revamp underway

Read the full weekly report ↓

Meet the team behind Curetopia.

Scientists who have spent decades advancing treatments for rare diseases.

Ethan Perlstein, Ph.D. (
@eperlste
)founded Perlara and Curetopia, pioneering patient-led biotech and translational research.

Kristin Kantautas, Ph.D. (
@wolfeofscience
) is a molecular geneticist leading drug repurposing programs for congenital metabolic disorders.

Mathuravani Thevandavakkam, Ph.D. is a synthetic biologist pushing yeast-model–based therapies for underserved communities.

Shiri Zakin, Ph.D. is a mitochondrial disease specialist with more than 20 years of experience driving patient-centered drug discovery.